FMS250516P35000
- 0.00
- 0.000.00%
Fresenius Medical Care Newsroom
Top Gap Ups and Downs on Thursday: AZN, MELI, APP and More
Berenberg Bank Maintains Fresenius Medical Care(FMS.US) With Buy Rating, Maintains Target Price $28.9
Fresenius Medical Care Outlines 2025 Operating Income Growth Targets Amid Strategic Transformations
Truist Financial Maintains Fresenius Medical Care(FMS.US) With Hold Rating
Fresenius Medical Care To Go Ex-Dividend On May 27th, 2025 With 0.7871 USD Dividend Per Share
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)
Deutsche Bank Maintains Investment Decision on Fresenius Medical Post Upbeat Q1 Earnings
Goldman Sachs Sticks to Their Buy Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)
Berenberg Bank Keeps Their Buy Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)
Research Alert: CFRA Keeps Sell Opinion On Adss Of Fresenius Medical Care
Top Gap Ups and Downs on Tuesday: PLTR, VRTX, CEG and More
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
Fresenius Medical Care Q1 Adjusted Earnings, Revenue Rise; Fiscal 2025 Outlook Confirmed
Express News | Fresenius Medical Care Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Earnings Flash (FMS) Fresenius Medical Care Posts Q1 Adjusted EPS 0.84 Euros
Express News | Fresenius Medical Care Expects FY 2025 Revenue to Grow by a Low Single-digit Percentage
Fresenius Medical Care Q1 Adj. EPS $0.44 Beats $0.38 Estimate, Sales $5.13B Beat $4.74B Estimate
Press Release: Fresenius Medical Care Starts 2025 With Strong Organic Revenue and Income Growth
6-K: Report of foreign private issuer (related to financial reporting)
Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Hold From UBS